Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 16 September, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 543520 | NSE: GLHRL

Global Longlife Hospital and Research Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: September 13, 2024, 10:02 pm

Market Cap 41.0 Cr.
Current Price 39.0
High / Low61.7/27.0
Stock P/E
Book Value 24.7
Dividend Yield0.00 %
ROCE2.04 %
ROE3.41 %
Face Value 10.0
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

Competitors of Global Longlife Hospital and Research Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gian Lifecare Ltd 24.4 Cr. 23.629.0/18.55.90 19.00.00 %29.1 %24.6 % 10.0
Fortis Malar Hospitals Ltd 112 Cr. 59.5108/44.0 58.471.4 %3.29 %9.12 % 10.0
Family Care Hospitals Ltd 46.8 Cr. 8.6610.4/6.234.18 10.80.58 %15.4 %24.1 % 10.0
Dr Lalchandani Labs Ltd 9.09 Cr. 21.035.0/15.714.7 22.00.00 %6.53 %6.95 % 10.0
Dolphin Medical Services Ltd 3.05 Cr. 2.023.25/1.46 6.670.00 %0.83 %0.99 % 10.0
Industry Average14,617.47N/A46.33N/AN/A11.5511.37N/A

Quarterly Result

MonthSep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024
Sales19.9412.8711.8011.7012.331.18
Expenses13.1811.6110.039.449.624.20
Operating Profit6.761.261.772.262.71-3.02
OPM %33.90%9.79%15.00%19.32%21.98%-255.93%
Other Income0.070.160.070.170.020.04
Interest0.091.310.200.200.410.36
Depreciation0.580.570.580.590.610.64
Profit before tax6.16-0.461.061.641.71-3.98
Tax %0.00%-78.26%29.25%35.37%39.77%-19.10%
Net Profit6.17-0.100.761.071.03-3.22
EPS in Rs8.81-0.140.721.020.98-3.07

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Sales33.4433.3232.7032.4423.3813.51
Expenses26.6129.8827.2624.1419.3013.82
Operating Profit6.833.445.448.304.08-0.31
OPM %20.42%10.32%16.64%25.59%17.45%-2.29%
Other Income0.080.030.060.170.240.06
Interest2.072.412.441.620.450.77
Depreciation2.152.131.311.141.171.25
Profit before tax2.69-1.071.755.712.70-2.27
Tax %49.07%-18.69%-16.57%37.30%32.59%-3.52%
Net Profit1.36-0.862.053.571.83-2.19
EPS in Rs1.94-1.232.935.101.74-2.09
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-163.24%338.37%74.15%-48.74%-219.67%
Change in YoY Net Profit Growth (%)0.00%501.61%-264.23%-122.89%-170.93%

Global Longlife Hospital and Research Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2019-2020 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:-17%
3 Years:-26%
TTM:-42%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:%
TTM:-220%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:-17%
Return on Equity
10 Years:%
5 Years:3%
3 Years:3%
Last Year:-3%

Last Updated: Unknown

Balance Sheet

Last Updated: Unknown

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Equity Capital7.007.007.007.0010.5010.50
Reserves5.354.496.689.9653.7915.43
Borrowings27.1823.5117.048.699.2912.74
Other Liabilities3.776.926.068.332.363.06
Total Liabilities43.3041.9236.7833.9875.9441.73
Fixed Assets20.1718.7217.4616.7116.5217.27
CWIP0.000.000.000.001.030.00
Investments0.100.100.470.100.100.03
Other Assets23.0323.1018.8517.1758.2924.43
Total Assets43.3041.9236.7833.9875.9441.73

Reserves and Borrowings Chart

Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 5.403.906.889.42-40.42-5.07
Cash from Investing Activity -0.33-0.040.020.01-1.90-0.82
Cash from Financing Activity -4.77-3.05-7.22-9.6645.702.67
Net Cash Flow0.310.81-0.33-0.223.38-3.22

Free Cash Flow

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-20.35-20.07-11.60-0.39-5.21-13.05

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days94.8568.6887.51100.25151.43
Inventory Days169.49157.9734.4688.9869.12
Days Payable229.91391.69138.68432.74110.43
Cash Conversion Cycle34.44-165.03-16.71-243.52110.13
Working Capital Days82.8578.2157.8236.34433.07
ROCE %3.81%12.75%26.22%6.35%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters54.29%54.29%54.29%54.29%54.29%54.29%54.29%54.29%54.29%
Public45.71%45.70%45.72%45.71%45.71%45.72%45.71%45.71%45.72%
No. of Shareholders1,0119489378888898809359471,010

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-2.081.795.112.92-2.02
Diluted EPS (Rs.)-2.081.795.112.92-2.02
Cash EPS (Rs.)-0.892.856.745.612.27
Book Value[Excl.RevalReserv]/Share (Rs.)24.7061.2324.2319.5413.34
Book Value[Incl.RevalReserv]/Share (Rs.)24.7061.2324.2319.5413.34
Revenue From Operations / Share (Rs.)12.8722.3846.8846.7247.92
PBDIT / Share (Rs.)-0.234.0711.798.675.49
PBIT / Share (Rs.)-1.432.9610.155.981.20
PBT / Share (Rs.)-2.162.588.162.51-2.24
Net Profit / Share (Rs.)-2.081.745.112.92-2.02
PBDIT Margin (%)-1.8318.1825.1418.5611.46
PBIT Margin (%)-11.0813.2221.6612.812.51
PBT Margin (%)-16.7611.5217.405.37-4.67
Net Profit Margin (%)-16.197.7710.896.25-4.21
Return on Networth / Equity (%)-8.432.8421.0614.96-15.15
Return on Capital Employeed (%)-5.094.5635.1915.943.13
Return On Assets (%)-5.242.4010.515.56-3.57
Long Term Debt / Equity (X)0.130.050.160.911.87
Total Debt / Equity (X)0.490.140.510.911.87
Asset Turnover Ratio (%)0.220.420.920.850.82
Current Ratio (X)0.314.280.821.131.21
Quick Ratio (X)0.284.170.751.061.04
Inventory Turnover Ratio (X)11.570.000.000.000.00
Interest Coverage Ratio (X)-0.3210.675.902.501.60
Interest Coverage Ratio (Post Tax) (X)-1.855.563.551.840.41
Enterprise Value (Cr.)53.3552.710.000.000.00
EV / Net Operating Revenue (X)3.952.240.000.000.00
EV / EBITDA (X)-215.5712.330.000.000.00
MarketCap / Net Operating Revenue (X)3.032.000.000.000.00
Price / BV (X)1.580.730.000.000.00
Price / Net Operating Revenue (X)3.032.000.000.000.00
EarningsYield-0.050.030.000.000.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: ₹12.89

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 66.95% compared to the current price ₹39.00

Default values used*: Default value of 15 for Stock P/E is used

Intrinsic Value: 11.39

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 70.79% compared to the current price ₹39.00

Default values used*: Default value of 15 for Stock P/E is used

Last 5 Year EPS CAGR: -11.67%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Cash Conversion Cycle of -46.78, which is a positive sign.
  2. The company has shown consistent growth in sales (28.13 cr) and profit (1.59 cr) over the years.
  1. The stock has a low average ROCE of 8.19%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 114.72, which may not be favorable.
  3. The company has higher borrowings (16.41) compared to reserves (15.95), which may suggest financial risk.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Global Longlife Hospital and Research Ltd:
    1. Net Profit Margin: -16.19%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -5.09% (Industry Average ROCE: 11.55%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: -8.43% (Industry Average ROE: 11.37%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): -1.85
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.28
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 0 (Industry average Stock P/E: 46.33)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.49
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Global Longlife Hospital and Research Ltd. is a Public Limited Listed company incorporated on 20/01/2012 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L85110GJ2012PLC068700 and registration number is 068700. Currently company belongs to the Industry of Hospitals & Medical Services. Company’s Total Operating Revenue is Rs. 32.82 Cr. and Equity Capital is Rs. 7.00 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Hospitals & Medical ServicesGlobal Hospital, Opp. Auda Garden, Ahmedabad Gujarat 380054investor@globalhospital.co.in
http://www.globalhospital.co.in
Management
NamePosition Held
Mr. Sureshkumar JaniChairman & Executive Director
Mr. Dhruv JaniManaging Director
Mrs. Sucheta JaniNon Executive Director
Mr. Manasvi ThaparIndependent Director
Mr. Sandeep ShahIndependent Director

FAQ

What is the latest fair value of Global Longlife Hospital and Research Ltd?

The latest fair value of Global Longlife Hospital and Research Ltd is ₹12.89.

What is the Market Cap of Global Longlife Hospital and Research Ltd?

The Market Cap of Global Longlife Hospital and Research Ltd is 41.0 Cr..

What is the current Stock Price of Global Longlife Hospital and Research Ltd as on 16 September 2024?

The current stock price of Global Longlife Hospital and Research Ltd as on 16 September 2024 is ₹39.0.

What is the High / Low of Global Longlife Hospital and Research Ltd stocks in FY 2024?

In FY 2024, the High / Low of Global Longlife Hospital and Research Ltd stocks is 61.7/27.0.

What is the Stock P/E of Global Longlife Hospital and Research Ltd?

The Stock P/E of Global Longlife Hospital and Research Ltd is .

What is the Book Value of Global Longlife Hospital and Research Ltd?

The Book Value of Global Longlife Hospital and Research Ltd is 24.7.

What is the Dividend Yield of Global Longlife Hospital and Research Ltd?

The Dividend Yield of Global Longlife Hospital and Research Ltd is 0.00 %.

What is the ROCE of Global Longlife Hospital and Research Ltd?

The ROCE of Global Longlife Hospital and Research Ltd is 2.04 %.

What is the ROE of Global Longlife Hospital and Research Ltd?

The ROE of Global Longlife Hospital and Research Ltd is 3.41 %.

What is the Face Value of Global Longlife Hospital and Research Ltd?

The Face Value of Global Longlife Hospital and Research Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Global Longlife Hospital and Research Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE